Gene to Health Limited primarily focuses on developing multi-omics predictive models for common disease risks, conducting biomedical big data analysis and modeling, and providing bioinformatics research services.

Gene to Health is a pioneer in Asia focused on polygenic scoring technology, leveraging millions of disease-related genetic variants and other omics data to predict over 1000 traits and diseases. Our core product suite, G2H, provides personalized health management solutions in one platform, including risk assessments for chronic diseases, dietary optimization, lifestyle advisory, and cancer risk prediction. We aim to revolutionize disease prevention and improve early disease intervention by integrating advanced genomic analysis, ML and AI.

We focus on developing multi-omics predictive models for common disease risks, conducting biomedical big data analytics and modeling, and offering omic-centered bioinformatics research services.

The primary target industries for our G2H platform are the pan-genomics sector and the general healthcare industries. G2H, with ability to assess disease risks like cardiovascular conditions from omics and health record data, positions it as a valuable tool for medical/genetic testing companies, medical institutions, research labs, and health management companies. Its flexibility allows integration with external datasets for specialized disease prediction, making it ideal for tailored services offered to clients in certain domains like cancer.

We are committed to establishing an integrated smart management platform that combines DNA data, omics data, medical and testing records, wearable device data, and other dynamic health information. Leveraging advancements in genomics and data science, we utilize big data to predict users' lifelong, broad-spectrum health phenotypes and disease risks, while providing personalized health advice and recommendations. This enables users to proactively prevent diseases and enjoy a healthy life.

In addition to serving numerous genetic testing companies, we target young families as our direct users. We drive long-term growth through subscription models, additional purchases, and partnerships with other health service companies. We are also exploring applications in areas such as agriculture, livestock, and the pet industry. Our ultimate goal is to create a broader ecosystem that integrates multiple data sources centered around DNA genetic data, driving diverse precision medicine services.

基因智健有限公司主要致力于开发多组学预测模型，以评估常见疾病的风险，进行生物医学大数据分析和建模，并提供生物信息学研究服务。

基因智健是亚洲的先驱，专注于多基因评分技术，利用数百万个与疾病相关的基因变异和其他组学数据，预测超过1000种性状和疾病。我们的核心产品套件G2H，提供一站式个性化健康管理解决方案，包括慢性病风险评估、饮食优化、生活方式建议和癌症风险预测。我们旨在通过整合先进的基因组分析、机器学习和人工智能，彻底改变疾病预防并提升早期疾病干预效果。

我们专注于开发多组学预测模型，以评估常见疾病的风险，进行生物医学大数据分析和建模，并提供以组学为核心的生物信息学研究服务。

G2H平台的主要目标行业包括泛基因组学领域和通用医疗行业。G2H能够从组学数据和健康记录中评估心血管疾病等疾病风险，使其成为医疗/基因检测公司、医疗机构、研究实验室和健康管理公司等的宝贵工具。其灵活性使得可以与外部数据集进行整合，用于特定疾病预测，因此非常适合为某些领域如癌症等提供量身定制的服务。

我们致力于建立一个整合DNA数据、多组学数据、医疗和检测记录、可穿戴设备数据及其他动态健康信息的智慧管理平台。通过基因组学和数据科学的进步，我们利用大数据预测用户的终身健康表型和疾病风险，并提供个性化的健康建议与推荐。这使用户能够主动预防疾病，享受健康生活。

除了为众多基因检测公司提供服务外，我们还将年轻家庭作为直接目标用户。通过订阅模式、追加购买和与其他健康服务公司合作，我们推动长期增长。我们也在探索农业、畜牧业和宠物行业等领域的应用。我们的最终目标是创建一个以DNA基因数据为核心，整合多数据源的精准医学服务生态系统，推动多样化的精准医学服务。